专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012028922A8 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN 审中-公开
标题翻译：控制释放的MILNACIPRAN的药物组合物
公开(公告)号：WO2012028922A8
公开(公告)日：2013-04-11
申请号：PCT/IB2011001955
申请日：2011-08-26
申请人： LUPIN LTD , KULKARNI SHIRISHKUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
发明人： KULKARNI SHIRISHKUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
IPC分类号： A61K31/165 , A61K9/20 , A61K9/28
CPC分类号： A61K31/164 , A61K9/209 , A61K9/2095 , A61K9/2886 , A61K9/2893 , A61K31/165 , A61K31/4178 , A61K31/439 , A61K45/00 , A61K45/06 , A61K2300/00
摘要： A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts thereof is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents.
摘要翻译：提供了包含米那普仑或其药学上可接受的盐的控释药物组合物。药物组合物包含包含米那普仑或其药学上可接受的盐，药学上可接受的赋形剂的立即释放核心和包含速率控制剂的速释核心上的包衣。

2. 发明申请

WO2012028922A2 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN 审中-公开
标题翻译：控制释放的MILNACIPRAN的药物组合物
公开(公告)号：WO2012028922A2
公开(公告)日：2012-03-08
申请号：PCT/IB2011001955
申请日：2011-08-26
申请人： LUPIN LTD , KULKARNI SHIRISHKUMAR , KULKARNA RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
发明人： KULKARNI SHIRISHKUMAR , KULKARNA RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
IPC分类号： A61K31/165 , A61K9/20 , A61K9/28
CPC分类号： A61K31/164 , A61K9/209 , A61K9/2095 , A61K9/2886 , A61K9/2893 , A61K31/165 , A61K31/4178 , A61K31/439 , A61K45/00 , A61K45/06 , A61K2300/00
摘要： A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts thereof is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents.
摘要翻译：提供了包含米那普仑或其药学上可接受的盐的控释药物组合物。药物组合物包含包含米那普仑或其药学上可接受的盐，药学上可接受的赋形剂的立即释放核心和包含速率控制剂的速释核心上的包衣。

3. 发明申请

WO2011016057A3 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN 审中-公开
标题翻译：米非司酮的控制释放药物组合物
公开(公告)号：WO2011016057A3
公开(公告)日：2011-10-06
申请号：PCT/IN2010000520
申请日：2010-08-04
申请人： LUPIN LTD , KULKARNI SHIRISH KUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
发明人： KULKARNI SHIRISH KUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
IPC分类号： A61K9/20 , A61K31/165
CPC分类号： A61K9/2027 , A61K9/2013 , A61K9/2054 , A61K9/2086 , A61K9/209 , A61K9/2095 , A61K31/165
摘要： A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90 % of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type I (Basket) at 100 rpm for 2 hrs, followed by 900 ml Phosphate buffer pH 6.8 USP apparatus Type I (Basket) at 100 rpm. A process of preparing a controlled release pharmaceutical composition comprises: a) preparing a first layer comprising i) melting hydrophobic release controlling agent and Milnacipran or pharmaceutically acceptable salts thereof in it ii) cooling followed by sieving the melted mass to obtain granules and iii) lubricating the granules; and b) preparing a second layer comprising granules which comprises hydrophobic release controlling agent and optionally Milnacipran or pharmaceutically acceptable salts thereof.
摘要翻译：包含米那普仑或其药学上可接受的盐和疏水性释放控制剂的控释药物组合物。当在900ml 0.1N HCl，USP装置I型（篮）以100rpm进行2小时进行溶解时，该组合物释放总量的90％的米那普仑或其药学上可接受的盐，接着900 ml磷酸盐缓冲液pH 6.8 USP装置I型（篮）在100rpm下。制备控释药物组合物的方法包括：a）制备第一层，所述第一层包含i）将疏水释放控制剂和米那普仑或其药学上可接受的盐在其中熔融ii）冷却，然后过滤熔融物质以获得颗粒，和iii）润滑颗粒; 和b）制备包含颗粒的第二层，所述颗粒包含疏水释放控制剂和任选的米那普仑或其药学上可接受的盐。

4. 发明申请

WO2009125432A2 GAS EMPOWERED EXPANDABLE DRUG DELIVERY SYSTEMS 审中-公开
标题翻译：气体可扩展的药物输送系统
公开(公告)号：WO2009125432A2
公开(公告)日：2009-10-15
申请号：PCT/IN2009000222
申请日：2009-04-01
申请人： LUPIN LTD , JUNGINGER HANS E , SADEGHI ASSAL M M , DORKOOSH FARID , AVADI MOHAMMAD REZA , RAFIEE-TEHRANI MORTEZA , JADHAV PANDHARINATH , KULKARNI RAJESH , KULKARNI SHIRISHKUMAR
发明人： JUNGINGER HANS E , SADEGHI ASSAL M M , DORKOOSH FARID , AVADI MOHAMMAD REZA , RAFIEE-TEHRANI MORTEZA , JADHAV PANDHARINATH , KULKARNI RAJESH , KULKARNI SHIRISHKUMAR
IPC分类号： A61K9/22 , A61K9/28
CPC分类号： A61K9/0007 , A61K9/0065 , A61K9/2009 , A61K9/2031 , A61K9/205 , A61K9/2846
摘要： An expandable drug delivery system comprising of one or more actives, force generating components, optionally containing one or more absorption modifiers and optionally containing one or more bioadhesive polymers. The active ingredient is entrapped into the nano/microsized particles of a mucoadhesive polymer matrix. The single unit dosage form is optionally coated with a degradable separating and/or enteric coating layer. An expandable drug delivery system for oral delivery consisting of a protein or peptide drug(s), force-generating components, with/with out absorption modifiers, wherein the composition is formulated to increase the residence time drug containing sub-units of the delivery system in the GIT, optionally coated with enteric polymers. An expandable drug delivery system consisting of a peptide drug, expandable polymer matrix, expanding force-generating component, which delivers drug to the absorbing membrane after a lag time followed by a burst release or sustained release.
摘要翻译：一种可膨胀药物递送系统，其包含一种或多种活性物质，产生力的组分，任选地含有一种或多种吸收改性剂和任选地含有一种或多种生物粘附性聚合物。将活性成分包埋在粘膜粘附聚合物基质的纳米/微粒化颗粒中。单一单位剂型任选地涂覆有可降解的分离和/或肠溶衣层。用于口服递送的可扩展药物递送系统，其由蛋白质或肽药物，具有/具有吸收改性剂的产生力的组分组成，其中配制组合物以增加包含递送系统的子单元的停留时间在GIT中，任选地涂覆有肠溶聚合物。一种由肽药物，可膨胀聚合物基质，膨胀力产生组分组成的可扩展药物递送系统，其在滞后时间之后将药物递送至吸收膜，随后是爆发释放或持续释放。

5. 发明专利

AU2011256928A1 Extended release formulation of pramipexole 未知
公开(公告)号：AU2011256928A1
公开(公告)日：2012-12-20
申请号：AU2011256928
申请日：2011-05-23
申请人： LUPIN LTD
发明人： KULKARNI SHIRISHKUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
IPC分类号： A61K9/20 , A61K31/428
摘要： An extended release formulation comprising pramipexole or pharmaceutically acceptable salts; derivatives; solvates; and isomers thereof, a weak acid and an extended release polymer. The formulation provides pH independent release profile of pramipexole.

6. 发明专利

MX2012001393A COMPOSICIONES FARMACÉUTICAS DE LIBERACIÓN CONTROLADA DE MILNACIPRAN. 未知
公开(公告)号：MX2012001393A
公开(公告)日：2012-08-03
申请号：MX2012001393
申请日：2010-08-04
申请人： LUPIN LTD
发明人： KULKARNI SHIRISH KUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
IPC分类号： A61K9/20 , A61K31/165
摘要： Una composición farmacéutica de liberación controlada que comprende Milnacipran o sales farmacéuticamente aceptables de los mismos y el agente de liberación de control hidrofóbico. La composición libera 90% de la cantidad total de Milnacipran o sales farmacéuticamente aceptables de los mismos entre 8 a 20 horas cuando la disolución se lleva a cabo en 900 ml de HCl0,1 N, USP aparato de tipo I (cestillo) a 100 rpm durante 2 horas, seguido por 900 ml de tampón de fosfato pH 6,8 USP aparato de tipo I (cestillo) a 100 rpm. Un proceso de preparación de una composición farmacéutica de liberación controlada comprende: a) preparar una primera capa que comprende i) fundir agente de liberación de control hidrofóbico y Milnacipran o sales farmacéuticamente aceptables de los mismos en ella ii) el enfriamiento seguido por tamizado de la masa fundida para obtener gránulos y iii) lubricante de gránulos, y b) preparar una segunda capa que comprende gránulos que comprende el agente de liberación de control hidrofóbico y, opcionalmente, Milnacipran o sales farmacéuticamente aceptables de los mismos.

7. 发明专利

CA2775091A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN 未知
公开(公告)号：CA2775091A1
公开(公告)日：2011-02-10
申请号：CA2775091
申请日：2010-08-04
申请人： LUPIN LTD
发明人： KULKARNI SHIRISH KUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
IPC分类号： A61K9/20 , A61K31/165
摘要： A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90 % of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type I (Basket) at 100 rpm for 2 hrs, followed by 900 ml Phosphate buffer pH 6.8 USP apparatus Type I (Basket) at 100 rpm. A process of preparing a controlled release pharmaceutical composition comprises: a) preparing a first layer comprising i) melting hydrophobic release controlling agent and Milnacipran or pharmaceutically acceptable salts thereof in it ii) cooling followed by sieving the melted mass to obtain granules and iii) lubricating the granules; and b) preparing a second layer comprising granules which comprises hydrophobic release controlling agent and optionally Milnacipran or pharmaceutically acceptable salts thereof.

8. 发明专利

ZA201209693B EXTENDED RELEASE FORMULATION OF PRAMIPEXOLE 未知
公开(公告)号：ZA201209693B
公开(公告)日：2013-08-28
申请号：ZA201209693
申请日：2012-12-20
申请人： LUPIN LTD
发明人： KULKARIN SHIRSHKUMAR , JADHAV PANDHARINATH , KULKARIN RAJESH , TIWARI ASHISH
IPC分类号： A61K20060101

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式